Oxygen Of The Saccharide Radical Bonded Directly To A Polycyclo Ring System Of Four Carbocyclic Rings (e.g., Daunomycin, Etc.) Patents (Class 514/34)
-
Publication number: 20140364387Abstract: Provided herein are bitter taste receptor ligands, related agents, combinations, compositions, methods and systems for modulating release of a metabolic hormone in vitro or in vivo from cells of the GI tract of an individual.Type: ApplicationFiled: June 30, 2014Publication date: December 11, 2014Inventors: William A. GODDARD, III, Mark MENNA, Stephan PANDOL, Ravinder ABROL
-
Publication number: 20140363522Abstract: The present invention concerns methods and compositions for the inhibition or reduction of the primary tumor and metastasis by inhibition of fatty acid binding proteins.Type: ApplicationFiled: May 13, 2014Publication date: December 11, 2014Inventors: Ernst LENGYEL, Kristin NIEMAN, Hilary KENNY
-
Publication number: 20140356414Abstract: A liposome composition that is useful for treating a subject in need of cancer treatment includes a cross-linked multilamellar liposome having an exterior surface and an interior surface. The interior surface defines a central liposomal cavity. The multilamellar liposome includes at least a first lipid bilayer and a second lipid bilayer. The first lipid bilayer is covalently bonded to the second lipid bilayer. At least one anticancer compound is disposed within the multilamellar liposome. Methods for treating subjects are also provided.Type: ApplicationFiled: June 3, 2014Publication date: December 4, 2014Applicant: University of Southern CaliforniaInventors: Pin WANG, Michael KK WONG, Andrew GRAY, Kye-Il JOO, Yarong LIU
-
Publication number: 20140357588Abstract: Methods of preparing highly purified steviol glycosides, particularly rebaudiosides A, D and M are described. The methods include utilizing recombinant microorganisms for converting various staring compositions to target steviol glycosides. In addition, novel steviol glycosides reb D2 and reb M2 are disclosed, as are methods of preparing the same. The highly purified rebaudiosides are useful as non-caloric sweetener in edible and chewable compositions such as any beverages, confectioneries, bakery products, cookies, and chewing gums.Type: ApplicationFiled: May 27, 2014Publication date: December 4, 2014Applicants: Purecircle SDN BHD, The Coca-Cola CompanyInventors: Avetik MARKOSYAN, Indra PRAKASH, Cynthia BUNDERS, Pankaj SONI, Jarrin CYRILLE, Aurélien BADIE, Robert ter HALLE
-
Publication number: 20140356439Abstract: Lipidated micro- or macroparticles are prepared by covalently linking a glycoprotein, typically collagen, with at least one lipid. An amino group in the glycoprotein is joined with a primary amine in the lipid. These particles can be used to encapsulate active ingredients, such as drugs.Type: ApplicationFiled: August 14, 2014Publication date: December 4, 2014Inventors: Rimona MARGALIT, Dan PEER
-
Patent number: 8900589Abstract: The present invention relates to conjugates of therapeutically useful anthracyclines with carriers such as polyclonal and monoclonal antibodies, proteins or peptides of natural or synthetic origin; methods for their preparation, pharmaceutical composition containing them and use thereof in treating certain mammalian tumors.Type: GrantFiled: July 14, 2009Date of Patent: December 2, 2014Assignee: Genetech, Inc.Inventors: Italo Beria, Michele Caruso, John A. Flygare, Vittoria Lupi, Rita Perego, Paul Polakis, Andrew Polson, Matteo Salsa, Susan D. Spencer, Barbara Valsasina, Robert L. Cohen
-
Patent number: 8900565Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.Type: GrantFiled: November 21, 2012Date of Patent: December 2, 2014Assignee: Pharmacyclics, Inc.Inventors: Joseph J. Buggy, Sriram Balasubramanian, Erik Verner, Vincent W. F. Tai, Chang-Sun Lee
-
Publication number: 20140348900Abstract: The present invention provides for a process for preparing liposomes, lipid discs, and other lipid nanoparticles using a multi-port manifold, wherein the lipid solution stream, containing an organic solvent, is mixed with two or more streams of aqueous solution (e.g., buffer). In some aspects, at least some of the streams of the lipid and aqueous solutions are not directly opposite of each other. Thus, the process does not require dilution of the organic solvent as an additional step. In some embodiments, one of the solutions may also contain an active pharmaceutical ingredient (API). This invention provides a robust process of liposome manufacturing with different lipid formulations and different payloads. Particle size, morphology, and the manufacturing scale can be controlled by altering the port size and number of the manifold ports, and by selecting the flow rate or flow velocity of the lipid and aqueous solutions.Type: ApplicationFiled: March 13, 2014Publication date: November 27, 2014Applicant: Cureport, Inc.Inventor: De-Min Zhu
-
Publication number: 20140348854Abstract: The invention provides compositions and methods for utilizing human epididymal secretory protein E4 (HE4) in the prevention and treatment of cancer and other human diseases.Type: ApplicationFiled: June 6, 2012Publication date: November 27, 2014Applicant: WOMEN & INFANTS' HOSPITAL OF RHODE ISLANDInventors: Richard G. Moore, Rakesh K. Singh
-
Patent number: 8895055Abstract: The present invention provides a nanodisc without a membrane scaffold protein. The nanodisc includes a telodendrimer and a lipid; the nanodisc does not include a membrane scaffold protein. The telodendrimer has the general formula PEG-L-D-(R)n, wherein D is a dendritic polymer; L is a bond or a linker linked to the focal point group of the dendritic polymer; each PEG is a poly(ethylene glycol) polymer; each R is and end group of the dendritic polymer, or and end group with a covalently bound hydrophobic group, hydrophilic group, amphiphilic compound, or drug; and subscript n is an integer from 2 to 20. Methods of making the nanodiscs are also provided.Type: GrantFiled: December 19, 2012Date of Patent: November 25, 2014Assignee: The Regents of the University of CaliforniaInventors: Kit S. Lam, Juntao Luo, Joyce S. Lee
-
Patent number: 8895069Abstract: The present invention relates to a drug delivery composition comprising a hyaluronic acid-peptide conjugate micelle and a production method thereof. According to the drug delivery composition and the production method of the drug-loaded, hyaluronic acid-peptide conjugate micelle of the present invention, the reaction for encapsulating can proceed in a mixed solvent of an aqueous solvent and an organic solvent. Therefore, the present invention can be applied to various types of water-insoluble active components and the biocompatible and biodegradable derivative can encapsulate a drug to provide a drug-loaded micelle, which is safe to be applied for human bodies. Moreover, the micelle has a therapeutic effect from the peptide contained therein, which can act in combination with the drug as packing therein. Therefore, the drug delivery composition and its production method can be utilized in the field of producing a sustained release formulation with an extended duration of the medicinal effect.Type: GrantFiled: December 15, 2011Date of Patent: November 25, 2014Assignee: Postech Academy-Industry FoundationInventors: Sei Kwang Hahn, Choun-Ki Joo, Yoon Keun Kim, Seung Kew Yoon, Eun Ju Oh, Ki Su Kim, Hyemin Kim, Kitae Park, Jeong-A Yang, Jun-Sub Choi, You Me Tae, Wonhee Hur
-
Publication number: 20140341849Abstract: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.Type: ApplicationFiled: August 4, 2014Publication date: November 20, 2014Inventors: Deng PAN, Masha Kocherginsky, Suzanne D. Conzen
-
Publication number: 20140335132Abstract: This invention describes nanocrystalline cellulose (NCC) for use as a drug delivery excipient. NCC binds significant quantities of water soluble, ionizable drugs, e.g., tetratcycline and doxorubicin, which are released rapidly over a one day period. A surfactant such as cetyl trimethylammonium bromide (CTAB) can bind to the surface of NCC and increase the zeta potential in a concentration-dependent manner from ?55 to 0 mV. NCC with CTAB modified surfaces can bind significant quantities of the hydrophobic drugs such as anticancer drugs docetaxel, paclitaxel and etoposide. These drugs were released in a controlled manner over a 2-day period. The NCC-CTAB nanocomplexes were found to bind to KU-7 cells and evidence of cellular uptake was observed.Type: ApplicationFiled: November 22, 2011Publication date: November 13, 2014Inventors: Helen Mary Burt, John Kevin Jackson, Wadood Yasser Hamad
-
Publication number: 20140335048Abstract: This disclosure relates, at least in part, to a method of treatment. In one embodiment, the method of treatment comprises administering to a subject in need of such treatment a first therapeutic agent including compound (1): or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially.Type: ApplicationFiled: July 25, 2014Publication date: November 13, 2014Applicant: ONCOCEUTICS, INC.Inventors: Martin STOGNIEW, Joshua E. ALLEN
-
Patent number: 8883199Abstract: N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in association with surgery, chemotherapy or hormone therapy treatment or radiotherapy, for use in the treatment of cancer, characterized in that it is administered for 4 consecutive days, that period being followed by 3 consecutive days without any administration of compound of formula (I), with the proviso that the chemotherapy is not FOLFOX.Type: GrantFiled: September 6, 2012Date of Patent: November 11, 2014Assignees: Les Laboratoires Servier, Pharmacyclics, Inc.Inventors: Ioana Kloos, Renata Robert, Anne Jacquet-Bescond, Stephane Depil, Marylore Chenel, Sylvain Fouliard, Sriram Balasubramanian
-
Patent number: 8883749Abstract: The present invention provides small molecules useful to affect cancer cells, along with related methods. The present compounds, formulations, kits and methods are useful for a variety of research, diagnostic and therapeutic purposes. STAT3 inhibitors, particularly LLL12, are disclosed. The STAT3 inhibitors are useful to treat breast cancer in general and breast cancer initiating cells in particular.Type: GrantFiled: November 24, 2010Date of Patent: November 11, 2014Assignees: The Ohio State University, Nationwide Children's Hospital, Inc.Inventors: Pui-Kai Li, Chenglong Li, Jiayuh Lin
-
Publication number: 20140328931Abstract: The present invention provides, among other things, a particle which includes a core comprised of self-assembled one or more nucleic acid molecules, the core being characterized by an ability to adopt at least two configurations: a first configuration having a first greatest dimension greater than 2 ?m and; a second configuration having a second greatest dimension less than 500 nm, wherein addition of a film coating converts the core from its first configuration to its second configuration. Methods of making and using of provided particles are also disclosed.Type: ApplicationFiled: February 26, 2014Publication date: November 6, 2014Applicant: Massachusetts Institute of TechnologyInventors: Paula T. Hammond, Jong Bum Lee, Young Hoon Roh
-
Publication number: 20140328863Abstract: This invention relates to methods of inducing differential stress resistance in a subject with cancer by starving the subject for a short term, administering a cell growth inhibitor to the subject, or reducing the caloric or glucose intake by the subject. The induced differential stress resistance results in improved resistance to cytotoxicity in normal cells, which, in turn, reduces cytotoxic side-effects due to chemotherapy, as well as improved effectiveness of chemotherapeutic agents.Type: ApplicationFiled: May 9, 2014Publication date: November 6, 2014Applicant: University of Southern CaliforniaInventor: Valter LONGO
-
Publication number: 20140328919Abstract: Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making the polymer-agent conjugates and particles, methods of storing the particles and methods of analyzing the particles.Type: ApplicationFiled: December 17, 2013Publication date: November 6, 2014Applicant: CERULEAN PHARMA INC.Inventors: Jerry Zhang, Pei-Sze Ng
-
Publication number: 20140328904Abstract: The present disclosure relates generally to compositions and methods for treating cancer with a glucopyranosyl lipid A (GLA) in the absence of antigen.Type: ApplicationFiled: July 17, 2014Publication date: November 6, 2014Inventors: Carlos V. Paya Cuenca, Jan Henrik Ter Meulen
-
Publication number: 20140328759Abstract: Various lipid nanoparticles are disclosed, including nanoparticles comprising a lipid bilayer comprising a phospholipid, a sterol, a polyethylene glycol-lipid surrounding an aqueous core which comprises a therapeutic and/or diagnostic agent and nanoparticles comprising a lipid monolayer surrounding a hydrophobic core. Of particular interest are limit size lipid nanoparticles with a diameter from 10-100 nm. Such lipid nanoparticles are the smallest particles possible for a specific particle composition. Methods and apparatus for preparing such limit size lipid nanoparticles are disclosed.Type: ApplicationFiled: October 25, 2012Publication date: November 6, 2014Applicant: THE UNIVERSITY OF BRITISH COLUMBIAInventors: Pieter R. Cullis, Igor V. Jigaltsev, James R. Taylor, Timothy Leaver, Andre Wild, Nathan Maurice Belliveau
-
Publication number: 20140328899Abstract: The present disclosure provides liposomes comprising a membrane and an intraliposomal aqueous water phase, the membrane comprising at least one liposome forming lipid and the intraliposomal aqueous water phase comprises a salt of a bisphosphonate together with an amphipathic weak base agent (PLAD). An example of a liposome is one comprising co encapsulated in the intraliposomal aqueous water phase N-containing bisphosphonate, such as alendronate, and an anthracycline such as doxorubicin which was shown to increase survival as compared to Doxil or to administrations of liposomal alendronate (PLA) and Doxil (separate liposomes). Such liposomes may carry a targeting moiety exposed at the liposome's outer surface, for example, conjugate of folic acid as a targeting moiety to folate receptor (FT-PLAD). Also provided by the present disclosure is a method of preparing the liposomes and methods of use of the liposomes, at times, in combination with additional active ingredients, such as ?? T-cells.Type: ApplicationFiled: July 7, 2012Publication date: November 6, 2014Applicants: SHAARE ZEDEK MEDICAL CENTER, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.Inventors: Alberto A. Gabizon, Yechezkel Barenholz, Hilary Shmeeda
-
Publication number: 20140328944Abstract: This invention encompasses a novel composition comprising silenced CTBP-1 combined with a compound selected from among 5-FU, Cisplatin and Epirubicin. The invention further relates to a method of treating gastric cancer with a combination of siRNA silenced CTBP-1 and a compound selected from among 5-FU, Cisplatin and Epirubicin.Type: ApplicationFiled: May 2, 2013Publication date: November 6, 2014Inventors: Manuel Gidekel, Carolina Bizama, Osvaldo Podhajcer
-
Patent number: 8877720Abstract: Disclosed are compounds represented by formula (I), pharmaceutically acceptable salts thereof, solvates thereof, and solvates of the pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, W and are as defined in the present application.Type: GrantFiled: November 3, 2010Date of Patent: November 4, 2014Assignees: Tianjin Hemay Bio-Tech Co., Ltd., Tianjin Michele Sci-Tech Development Co., Ltd.Inventor: Hesheng Zhang
-
Publication number: 20140323421Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase DOT1L and one or more therapeutic agents, particularly anticancer agents, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.Type: ApplicationFiled: March 14, 2014Publication date: October 30, 2014Applicant: EPIZYME, INC.Inventors: Christine Klaus, Maria Alejandra Raimondi, Scott R. Daigle, Roy MacFarlane Pollock
-
Publication number: 20140314750Abstract: Described herein are methods of predicting the risk of developing ovarian cancer recurrence of a subject comprising the steps of detecting the expression levels of at least four of the six genes selected from the group consisting of AKT2, KRAS, RAC1, CALM3, RPS6KA2 and YWHAB or the gene products thereof, wherein the presence of increased expression levels of the genes or the gene products is predictive of the increased risk of developing ovarian cancer recurrence in the subject. Kits for practicing the methods are also disclosed.Type: ApplicationFiled: April 11, 2014Publication date: October 23, 2014Applicant: Wisconsin Alumni Research FoundationInventors: Christina Kendziorski Newton, Kevin Hasegawa Eng
-
Publication number: 20140315845Abstract: The invention provides 19-substituted geldanamycin derivatives, and pharmaceutically acceptable salts thereof that are potent Hsp90 binding agents useful for the treatment of, and/or the amelioration of symptoms of, cancer or neurodegenerative disorders.Type: ApplicationFiled: November 14, 2012Publication date: October 23, 2014Inventors: David Ross, David Siegal, Christopher J. Moody, Russell Richard Anthony Kitson
-
Publication number: 20140314878Abstract: The disclosure provides rifamycin and rifamycin derivative compositions, including rifabutin and rifabutin derivative compositions able to cause drug-sensitization in a cancer cell or inhibition of a cancer cell. The disclosure also provides methods of administering such compositions to cancer cells to sensitize them to drugs, such as chemotherapeutics, or directly inhibit them. The disclosure also provides methods of administering such compositions to increase reactive oxygen species (ROS), particularly superoxides, in cancer cells. The disclosure further provides methods of determining whether a cancer will respond to chemotherapeutics and whether to administer rifamycin or a rifamycin derivative based on ROS levels in cancer cells of a patient.Type: ApplicationFiled: July 2, 2014Publication date: October 23, 2014Inventors: James Sacchettini, Niam Zhou, Dwight Baker, Steven A. Maxwell, Deeann Wallis
-
Publication number: 20140315844Abstract: Exemplary embodiments of the invention provide methods and compositions relating to a multi-gene signature, and subsets thereof, for predicting whether an individual with breast cancer will respond to chemotherapy based on expression of the genes in the multi-gene signature, as well as for prognosing risk of breast cancer metastasis.Type: ApplicationFiled: November 27, 2013Publication date: October 23, 2014Applicant: Celera CorporationInventors: Shirley KWOK, Alice WANG
-
Patent number: 8865663Abstract: An administration method comprising: determining a cancer type through (i) first data indicating that an Estrogen Receptor (ER) is negative and a Human Epidermal growth factor Receptor-2 (Her2) is negative, or (ii) second data indicating that at least one of the ER and the Her2 is positive; and when the cancer type is determined through (i) the first data indicating that the ER is negative and the Her2 is negative: first performing a docetaxel administration cycle comprising administrating docetaxel to a patient multiple times at certain intervals; and then performing a 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) administration cycle comprising administrating 5-fluorouracil, epirubicin, and cyclophosphamide to the patient multiple times at certain intervals, and when the cancer type is determined through (ii) the second data indicating that at least one of the ER and Her2 is positive: first performing the FEC administration cycle; and then performing the docetaxel administration cycle.Type: GrantFiled: January 26, 2009Date of Patent: October 21, 2014Assignee: Japan Breast Cancer Research GroupInventors: Masakazu Toi, Hiroji Iwata, Katsumasa Kuroi, Seigo Nakamura, Shinji Ohno, Norikazu Masuda, Kenjiro Aogi, Nobuaki Sato, Futoshi Akiyama, Masafumi Kurosumi, Hitoshi Tsuda
-
Publication number: 20140309184Abstract: Embodiments of the present disclosure relate to methods and compositions for treating a subject with ovarian cancer. Some embodiments include treating a subject with a particular combination of chemotherapeutic agents.Type: ApplicationFiled: July 20, 2012Publication date: October 16, 2014Applicant: UNIVERSITY OF SOUTH ALABAMAInventors: Rodney P. Rocconi, Lalita Samant
-
Publication number: 20140308360Abstract: The invention provides multivalent surface-crosslinked micelle (SCM) particles, crosslinked reverse micelle (CRM) particles, and methods of making and using them. The SCM particles can be used, for example, to inhibit a virus or bacteria from binding to a host cell. The inhibition can be used in therapy for the flu, cancer, or AIDS. The CRM particles can be used, for example, to prepare metal nanoparticles or metal alloy nanoparticles, or they can be used in catalytic reactions.Type: ApplicationFiled: June 26, 2014Publication date: October 16, 2014Inventor: Yan Zhao
-
Publication number: 20140308351Abstract: Methods are described for producing non-immunogenic nanoparticles from protein sources by controlling the pH in a nanoprecipitation process. The nanoparticles that are produced by the disclosed methods range in diameter size from about 100 ran to about 400 nm, with a preferred diameter size of from approximately 100 nm to approximately 300 nm, thereby rendering them non-immunogenic. The invention further discloses methods for producing nanoconjugates that are suitable for a variety of therapeutic, diagnostic and other uses.Type: ApplicationFiled: March 10, 2014Publication date: October 16, 2014Applicant: South Dakota State UniversityInventors: Omathanu P. Perumal, Satheesh K. Podaralla, Radhey S Kaushik
-
Publication number: 20140309183Abstract: Disclosed herein are compositions comprising at least two compounds in a therapeutically effective composition for treating cancer. Compositions include a single oral dosage form comprising at least two anti-cancer compounds. Also disclosed herein are methods of making and using such compositions.Type: ApplicationFiled: August 24, 2011Publication date: October 16, 2014Inventor: David Kerr
-
Publication number: 20140308342Abstract: The present invention relates to chimeric (preferably, bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic cancer where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells. The compounds preferably covalently bind to the urokinase receptor and recruit native antibodies of the patient or subject where the antibodies can selectively degrade and/or deactivate targeted cancer cells through antibody-dependent cellular phagocytosis and/or antibody-dependent cellular cytotoxicity (ADCC) against a large number and variety of cancers, thus providing cancer cell death and/or an inhibition of growth, elaboration and/or metastasis of the cancer, including remission and cure of the patient's cancer.Type: ApplicationFiled: November 7, 2012Publication date: October 16, 2014Inventors: David A. Spiegel, Charles E. Jakobsche
-
Publication number: 20140301976Abstract: The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.Type: ApplicationFiled: June 20, 2014Publication date: October 9, 2014Inventors: Erik J. VERNER, Martin SENDZIK, Chitra BASKARAN, Joseph J. BUGGY, James ROBINSON
-
Publication number: 20140301961Abstract: Non-therapeutic cosmetic or dermatological use of at least one of a compound selected from the group consisting of: gibberellic acids, naringenins, N-acetylaspartic acids, ?-aescin, arachadonic acid, quercetin, vitexin and docosahexaenoic acid (ethyl ester). Suitably, the use is in the treatment of, and/or prevention of, at least one sign of skin ageing or at least one sign of a skin damage condition associated with ageing, wherein the sign of skin ageing or skin damage is present on skin of the face, body or the scalp of a subject.Type: ApplicationFiled: June 19, 2014Publication date: October 9, 2014Inventors: Johanna Maria GILLBRO, Alain Robert Pierre MAVON, Lucie DURACHER, Anke KLACK, Kevin CATTLEY
-
Publication number: 20140296173Abstract: A nanoparticulate composition is disclosed for the targeted therapeutic treatment of tumours. The stable self assembled nanocomposition according to the invention comprises (i) a carrier and targeting system comprising an optionally modified polyanion, and optionally a polycation, which may also be modified; at least one targeting agent which is linked to either the polycation/modified polycation or the polyanion/modified polyanion, or both; (ii) an active compound selected from the group of epirubicin and its pharmaceutically acceptable salts, especially hydrochloride; and optionally (iii) at least one complexing agent, metal ion and stabilizer/formulating agent. The invention furthermore relates to a process for the preparation of the above-mentioned composition, the therapeutic uses thereof, and pharmaceutical compositions containing the nanocomposition according to the invention.Type: ApplicationFiled: March 28, 2014Publication date: October 2, 2014Applicant: BBS NANOTECHNOLOGY LLC.Inventors: János BORBÉLY, Zsuzsanna BERÉNYI, István HAJDÚ
-
Publication number: 20140294818Abstract: In certain embodiments, the disclosure relates to methods of treating or preventing a PGAM1 mediated condition such as cancer or tumor growth comprising administering an effective amount of PGAM1 inhibitor, for example, an anthracene-9,10-dione derivative to a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, head and neck cancer, and leukemia, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof.Type: ApplicationFiled: October 11, 2012Publication date: October 2, 2014Applicant: EMORY UNIVERSITYInventors: Jing Chen, Taro Hitosugi, Sumin Kang
-
Publication number: 20140294851Abstract: Base-labile crosslinkers, base-labile conjugates comprising such crosslinkers, methods of their synthesis and use are disclosed.Type: ApplicationFiled: April 1, 2013Publication date: October 2, 2014Inventor: MARK QUANG NGUYEN
-
Publication number: 20140294983Abstract: A nanoparticulate composition for the targeted therapeutic treatment of tumours. The stable self assembled nanocomposition according to the invention comprises (i) a carrier and targeting system comprising an optionally modified polyanion, and optionally a polycation, which may also be modified; at least one targeting agent which is linked to either the polycation/modified polycation or the polyanion/modified polyanion, or both, or to the surface of the nanoparticle; (ii) an active compound selected from the group of doxorubicin and its pharmaceutically acceptable salts, especially hydrochloride; and optionally (iii) at least one complexing agent, a metal ion, a stabilizer/formulating agent, or a PEGylating agent. The present invention furthermore relates to a process for the preparation of the above-mentioned composition, the therapeutic uses thereof, and pharmaceutical compositions containing the nanocomposition according to the invention.Type: ApplicationFiled: December 19, 2013Publication date: October 2, 2014Applicant: BBS NANOTECHNOLOGY LTD.Inventors: János BORBÉLY, Zsuzsanna CSIKÓS, Ildikó SCHRIFFERTNE DENYICSKA
-
Publication number: 20140296174Abstract: The present invention provides a multifunctional platform suitable for biomedical applications. In particular, the invention includes a silk fibroin-based multifunctional device that enables both the sustained delivery of a drug and monitoring of such delivery in vivo.Type: ApplicationFiled: October 11, 2012Publication date: October 2, 2014Inventors: Fiorenzo Omenetto, David L. Kaplan
-
Patent number: 8846081Abstract: The present application relates to compositions comprising and methods of using a liposome comprising a pHLIP polypeptide, wherein a lipid bilayer of the liposome is substantially free of the pHLIP polypeptide.Type: GrantFiled: August 12, 2011Date of Patent: September 30, 2014Assignees: Rhode Island Board of Governors for Higher Education, Yale UniversityInventors: Yana K. Reshetnyak, Oleg A. Andreev, Donald M. Engelman
-
Publication number: 20140288162Abstract: Methods and compositions are provided for treating human synovial sarcoma (SS). Also provided are screens to identify therapeutics for the treatment of synovial sarcoma. These methods, compositions, and screens are based on the discovery that promoting the assembly of wild type BAF (also called mSWI/SNF) complexes in SS cells by increasing levels of wild type SS18 and/or decreasing levels of SS18-SSX fusion protein leads to the cessation of proliferation of malignant cells in synovial sarcoma.Type: ApplicationFiled: March 13, 2014Publication date: September 25, 2014Inventors: Cigall Kadoch, Gerald R. Crabtree
-
Publication number: 20140287027Abstract: The invention relates to the use of a composition comprising a corticosteroid encapsulated in a vesicle for the manufacture of a medicament for treating cancer, such as the use of a composition comprising a corticosteroid and liposomes, the liposomes comprising a non-charged vesicle-forming lipid, and optionally an amphipathic vesicle-forming lipid and/or a negatively charged vesicle-forming lipid. The invention further relates to a new pharmaceutical composition suitable for treating cancer, and especially solid primary and secondary tumors.Type: ApplicationFiled: May 28, 2014Publication date: September 25, 2014Applicant: Enceladus Pharmaceuticals B.V.Inventors: Raymond Michel Schiffelers, Josbert Maarten Metselaar, Grietje Molema, Gerrit Storm
-
Publication number: 20140287049Abstract: Embodiments provide systems, methods, and compositions for nanoparticle-based drug delivery to target cells or tissues. A drug delivery system may include a nanoparticle with a targeting component and a therapeutic component. The nanoparticle may have a predetermined number or valence of targeting molecules for multivalent interaction with a target cell or tissue. Binding of the targeting molecules to the target cell may result in receptor-mediated uptake of the nanoparticle by the target cell. The therapeutic component may be subsequently released within an endocytic vesicle of the target cell. Nanoparticle-based drug delivery systems as described herein may provide improved efficacy and/or reduced toxicity.Type: ApplicationFiled: November 5, 2012Publication date: September 25, 2014Inventors: Zihni Basar Bilgicer, Tanyel Kiziltepe Bilgicer, Jonathan Darryl Ashley, Jared Stefanick, Nathan J. Alves, Michael W. Handlogten
-
Publication number: 20140286902Abstract: A pharmaceutical combination comprising a platinum-containing anticancer agent, and an Hsp90 inhibitor according to the following formulae (I) & (Ia), a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables structural formulae are defined herein. Also provided is a method of treating a proliferative disorder such as cancer in a subject in need thereof, using the pharmaceutical combination described herein.Type: ApplicationFiled: November 1, 2012Publication date: September 25, 2014Inventor: David Proia
-
Publication number: 20140286938Abstract: The present invention relates to spiroketal compounds that are useful in methods of treating or preventing protozoal infections, parasitic infections, bacterial infections, cell proliferative disorders and anti inflammatory disorders. The spiroketal compounds are also useful as immunosuppressive agents, and also in methods of controlling pests.Type: ApplicationFiled: March 21, 2014Publication date: September 25, 2014Applicant: EcoBiotics LtdInventors: Paul Warren Reddell, Victoria Anne Gordon
-
Publication number: 20140271885Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications.Type: ApplicationFiled: February 11, 2014Publication date: September 18, 2014Applicant: Intezyne Technologies, Inc.Inventors: Kevin Sill, Tomas Vojkovsky
-
Publication number: 20140274927Abstract: A method of evaluating response to a taxane drug and/or anthracycline drug, the method comprising measuring a level of a TNF biomarker in a biological sample comprising the cancer cell after contacting the cancer cell with the taxane drug and/or anthracycline drug.Type: ApplicationFiled: January 3, 2014Publication date: September 18, 2014Inventors: Amadeo Mark Parissenti, Jason A. Sprowl